Abstract
Anti-SARS-CoV2 mRNA vaccines showed a blunted antibody (Ab) response in people with MS (pwMS) on high efficacy therapies, suggesting the need for a booster dose. We evaluated the kinetics of the production of anti-receptor binding domain (RBD) Immunoglobulins G (IgG) after the vaccination cycle and the booster in pwMS receiving ocrelizumab, fingolimod and cladribine. A significant increase of anti-RBD IgG seroconversion was observed after booster respect to the vaccination cycle. Results obtained from this study will be useful for the management of pwMS in relation to their disease modifying therapy (DMT) and for any future vaccination campaign.
Keywords: Anti-SARS-Cov2 vaccine; Booster; Multiple sclerosis; Third dose.
【저자키워드】 multiple sclerosis, booster, third dose, Anti-SARS-Cov2 vaccine, 【초록키워드】 IgG, Efficacy, vaccination, therapy, antibody, mRNA vaccine, Seroconversion, RBD, management, disease, booster dose, Therapies, dose, Anti-RBD IgG, significant increase, binding domain, Multiple, Result, evaluated, receiving, 【제목키워드】 Vaccine, therapy, anti-SARS-CoV-2, Humoral response, booster dose, patients treated,